Nab-P+Cb+PD1 Inhibitors as Neoadjuvant Therapy for Early TNBC
NCT06817525
·
clinicaltrials.gov ↗
PHASE2
Phase
RECRUITING
Status
64
Enrollment
OTHER_GOV
Sponsor class
Conditions
Triple-negative Breast Cancer
Interventions
DRUG:
6*Nab-P (d 1)+6*Cb ( d 1)+6*PD1 (d 1)
DRUG:
6*Nab-P (d 1,8,15)+6*Cb ( d 1)+6*PD1 (d 1)
Sponsor
Henan Cancer Hospital